| Literature DB >> 30988834 |
Yoko Yamada1, Shinji Watanabe2, Keinosuke Okamoto1,2,3, Sakae Arimoto1,2, Eizo Takahashi1,4,3, Kazuo Negishi4, Tomoe Negishi1,4.
Abstract
BACKGROUND: Chloroethylnitrosourea (CENU) derivatives, such as nimustine (ACNU) and carmustine (BCNU), are employed in brain tumor chemotherapy due to their ability to cross the blood-brain barrier. They are thought to suppress tumor development through DNA chloroethylation, followed by the formation of interstrand cross-links (ICLs) that efficiently block replication and transcription. However, the alkylation of DNA and ICLs may trigger genotoxicity, leading to tumor formation as a side effect of the chemotherapeutic treatment. Although the involvement of O 6-alkylguanine-DNA alkyltransferase (AGT) in repairing chloroethylated guanine (O 6-chloroethylguanine) has been reported, the exact lesion responsible for the genotoxicity and the pathway responsible for repairing it remains unclear.Entities:
Keywords: Carmustine (BCNU); Chloroethylnitrosourea; DNA repair; Escherichia coli; Interstrand cross-link (ICL); Nimustine (ACNU); Recombination
Year: 2019 PMID: 30988834 PMCID: PMC6449902 DOI: 10.1186/s41021-019-0123-x
Source DB: PubMed Journal: Genes Environ ISSN: 1880-7046
Fig. 1The structures of the mutagens used in this study
E. coli KA796 mutants used in this study and their spontaneous mutant frequencies
| Strain | Relevant genotype | Spontaneous mutant frequency | Ref. |
|---|---|---|---|
| NR12999 | KA796, | 0.24 ± 0.16 | [ |
| KT01121 | KA796, | 0.78 ± 0.27 | [ |
| NR12896 | KA796, | 59.6 ± 11.4 | [ |
| NR11102 | KA796, | 22.5 ± 9.63 | [ |
| NR12897 | KA796, | 43.0 ± 16.5 | [ |
| NR11312 | KA796, | 0.16 ± 0.1 | [ |
| ZA2102 |
| < 0.1 | [ |
| SW102 | 0.1 ± 0.5 | This study |
a: All mutants contain CC102 F’episome
b: All spontaneous mutant frequencies shown in this table were measured in this study
Fig. 2Mutant frequencies induced by BCNU (a, d), ACNU (b, e), and TMZ (c, f) in the wild-type (open circles), KT01121 (closed diamonds), NR12999 (closed triangles), and NR11312 (closed squares) strains. Statistical analysis was performed using the Student’s t test. **p < 0.01 and *p < 0.05 when compared to the mutation frequency of the wild-type strain. ††p < 0.01 and †p < 0.05 when compared to the mutant frequency of control without treatment
Fig. 3Cytotoxicity induced by BCNU (a, d), ACNU (b, e), and TMZ (c, f) in the wild-type (open circles), KT01121 (closed diamonds), NR12999 (closed triangles), and NR11312 (closed squares) strains. Statistical analysis was performed using the Student’s t test. **p < 0.01 and *p < 0.05 when compared to the mutant frequency of the wild-type strain
Fig. 4Frequency of mutations and cytotoxicity induced by BCNU (a, c) and ACNU (b, d) in the wild-type (open circles), NR12999 (closed triangles), NR11312 (closed squares), and SW102 (closed circles) strains. Statistical analysis was performed using the Student’s t test. **p < 0.01 and *p < 0.05 when compared to the mutation frequency of the wild-type strain. ††p < 0.01 and †p < 0.05 when compared to the mutant frequency of control without treatment
Mutant frequencies induced by ACNU and BCNU in E. coli series from CC101 to CC111
| Strain | ACNU | BCNU | ||||
|---|---|---|---|---|---|---|
| dose (mM) | MF (×10−7) | survival (%) | dose (mM) | MF (×10−7) | survival (%) | |
| CC101 | 0 | 0.24 ± 0.42 | 100 | 0 | 0.24 ± 0.21 | 100 |
| (AT to CG) | 1 | < 0.21 | 101.6 ± 6.5 | 0.5 | 0.72 ± 0.06 | 49.5 ± 4.2 |
| CC102 | 0 | 0.42 ± 0.43 | 100 | 0 | 0.31 ± 0.02 | 100 |
| (GC to AT) | 1 | 33.0 ± 5.74** | 102.1 ± 14.4 | 0.5 | 79.63 ± 23.6** | 48.3 ± 10.5 |
| CC103 | 0 | < 0.17 | 100 | 0 | < 0.11 | 100 |
| (GC to CG) | 1 | < 0.18 | 94.1 ± 11.1 | 0.5 | < 0.21 | 55.4 ± 3.9 |
| CC104 | 0 | 0.31 ± 0.27 | 100 | 0 | 0.45 ± 0.03 | 100 |
| (GC to TA) | 1 | 0.62 ± 0.55 | 100.5 ± 12.8 | 0.5 | 1.75 ± 1.85 | 60.2 ± 13.3 |
| CC105 | 0 | 0.64 ± 0.04 | 100 | 0 | 0.31 ± 0.53 | 100 |
| (AT to TA) | 1 | < 0.12 | 151.0 ± 15.7 | 0.5 | 0.40 ± 0.35 | 63.6 ± 9.5 |
| CC106 | 0 | < 0.16 | 100 | 0 | < 0.16 | 100 |
| (AT to GC) | 1 | < 0.13 | 108.4 ± 13.6 | 0.5 | < 0.22 | 57.6 ± 18.1 |
| CC107 | 0 | 10.56 ± 1.86 | 100 | 0 | 6.90 ± 0.88 | 100 |
| (+ 1 (G/C)) | 1 | 8.01 ± 1.60 | 107.6 ± 12.6 | 0.5 | 8.61 ± 1.54 | 65.8 ± 11.6 |
| CC108 | 0 | 4.58 ± 1.17 | 100 | 0 | 3.39 ± 1.04 | 100 |
| (+ 1 (G/C)) | 1 | 2.6 7± 0.70 | 111.9 ± 9.0 | 0.5 | 2.83 ± 2.18 | 87.1 ± 10.7 |
| CC109 | 0 | 58. 37± 7.21 | 100 | 0 | 43. 88± 3.17 | 100 |
| (+ 2 (CG/GC)) | 1 | 57.60 ± 12.7 | 109.2 ± 8.1 | 0.5 | 42.28 ± 13.38 | 91.4 ± 37.0 |
| CC110 | 0 | 0.27 ± 0.46 | 100 | 0 | 0.12 ± 0.20 | 100 |
| (+ 1 (A/T)) | 1 | 0.67 ± 0.30 | 141.2 ± 14.2 | 0.5 | 0.36 ± 0.32 | 75.3 ± 13.5 |
| CC111 | 0 | 3.47 ± 0.18 | 100 | 0 | 6.85 ± 1.49 | 100 |
| (−2 (A/T)) | 1 | 6.01 ± 2.21 | 67.4 ± 3.8 | 0.5 | 4.23 ± 0.76 | 90.6 ± 24.3 |
**; p < 0.01, significant increase from the corresponding control
Mutant frequencies of ACNU and BCNU induced in MMR-deficient strains
| Mutant frequency (× 10− 7) | |||||||
|---|---|---|---|---|---|---|---|
| Doses (mM) | ACNU | BCNU | |||||
| 0 | 0.5 | 1 | 0 | 0.5 | 1 | ||
| Strain | wild-type | 0.39 ± 0.15 | 22.0 ± 5.83 | 39.2 ± 7.72 | 0.59 ± 0.62 | 45.2 ± 27.2 | 118 ± 77.3 |
|
| 57.2 ± 9.11 | 71.8 ± 11.2 | 90.7 ± 9.15 | 49.6 ± 9.78 | 80.8 ± 6.43 | 158 ± 31.3 | |
|
| 15.5 ± 2.45 | 41.2 ± 2.60 | 96.4 ± 9.26* | 24.1 ± 5.76 | 100 ± 38.2 | 215 ± 72.7 | |
|
| 34.8 ± 7.26 | 50.2 ± 9.05 | 78.9 ± 7.72 | 32.2 ± 4.09 | 107 ± 30.0 | 188 ± 75.9 | |
These data are from 3 independent experiments with ACNU and from 2 independent experiments with BCNU
Statistical analysis was performed using the Student’s t test. *p < 0.05 compared with the mutant frequency for the wild-type
Summary
| ACNU | BCNU | |||
|---|---|---|---|---|
| Mutagenesis | Cytotoxicity | Mutagenesis | Cytotoxicity | |
| Repair | AGT | NER | AGT | NER |
| DNA | ICL | ICL | ||